167 related articles for article (PubMed ID: 38191022)
21. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
[TBL] [Abstract][Full Text] [Related]
22. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Vale CL; Fisher DJ; White IR; Carpenter JR; Burdett S; Clarke NW; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Rydzewska LH; Sweeney CJ; Spears MR; Sydes MR; Tierney JF
Ann Oncol; 2018 May; 29(5):1249-1257. PubMed ID: 29788164
[TBL] [Abstract][Full Text] [Related]
23. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Sydes MR; Spears MR; Mason MD; Clarke NW; Dearnaley DP; de Bono JS; Attard G; Chowdhury S; Cross W; Gillessen S; Malik ZI; Jones R; Parker CC; Ritchie AWS; Russell JM; Millman R; Matheson D; Amos C; Gilson C; Birtle A; Brock S; Capaldi L; Chakraborti P; Choudhury A; Evans L; Ford D; Gale J; Gibbs S; Gilbert DC; Hughes R; McLaren D; Lester JF; Nikapota A; O'Sullivan J; Parikh O; Peedell C; Protheroe A; Rudman SM; Shaffer R; Sheehan D; Simms M; Srihari N; Strebel R; Sundar S; Tolan S; Tsang D; Varughese M; Wagstaff J; Parmar MKB; James ND;
Ann Oncol; 2018 May; 29(5):1235-1248. PubMed ID: 29529169
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a U.S. Payer's Perspective.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Manag Care Spec Pharm; 2019 Feb; 25(2):225-234. PubMed ID: 30698095
[TBL] [Abstract][Full Text] [Related]
26. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract][Full Text] [Related]
27. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
28. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Morris MJ; Rumble RB; Basch E; Hotte SJ; Loblaw A; Rathkopf D; Celano P; Bangs R; Milowsky MI
J Clin Oncol; 2018 May; 36(15):1521-1539. PubMed ID: 29608397
[TBL] [Abstract][Full Text] [Related]
29. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
[TBL] [Abstract][Full Text] [Related]
30. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Xu L; Pachynski RK
Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573
[TBL] [Abstract][Full Text] [Related]
31. Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis.
Zhang PF; Xie D; Li Q
Front Public Health; 2021; 9():608375. PubMed ID: 33634066
[No Abstract] [Full Text] [Related]
32. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
33. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
García de Paredes Esteban JC; Alegre Del Rey EJ; Asensi Díez R
Farm Hosp; 2017 Jul; 41(4):550-558. PubMed ID: 28683707
[TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
[TBL] [Abstract][Full Text] [Related]
36. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
Barbier MC; Tomonaga Y; Menges D; Yebyo HG; Haile SR; Puhan MA; Schwenkglenks M
PLoS One; 2022; 17(11):e0277282. PubMed ID: 36327294
[TBL] [Abstract][Full Text] [Related]
37. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
Saad F; Chilelli A; Hui B; Muratov S; Ganguli A; North S; Shayegan B
J Med Econ; 2022; 25(1):583-590. PubMed ID: 35469527
[TBL] [Abstract][Full Text] [Related]
39. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer.
Lester-Coll NH; Ades S; Yu JB; Atherly A; Wallace HJ; Sprague BL
JAMA Netw Open; 2021 Jan; 4(1):e2033787. PubMed ID: 33439266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
